ORCID as entered in ROS
https://orcid.org/0000-0001-6072-8309
Select Publications
Journal articles
, 2000, 'Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya', JOURNAL OF CLINICAL MICROBIOLOGY, 38, pp. 2688 - 2695, http://dx.doi.org/10.1128/JCM.38.7.2688-2695.2000
, 2000, 'A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4(+) cell counts >= 350/mm(3) (vol 181, pg 1614, 2000)', JOURNAL OF INFECTIOUS DISEASES, 181, pp. 2122 - 2122, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000087923900051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2000, 'Erratum: A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ≥350/mm3 (Journal of Infectious Diseases (May 2000) 181 (1614-1621))', Journal of Infectious Diseases, 181, pp. 2122, http://dx.doi.org/10.1086/315531
, 2000, 'A randomised, open-label comparison of three highly active antiretroviral therapy regimes including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study', AIDS, 14, pp. 1171 - 1180
, 2000, 'A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand', AIDS, 14, pp. 2509 - 2513
, 2000, 'A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts ? 350/mm³', Journal of Infectious Diseases, 181, pp. 1614 - 1621
, 2000, 'Clinical trials of antiretroviral therapy in developing countries', Australian and New Zealand Journal of Medicine, pp. 3 - 4
, 2000, 'Lipodystrophy following antiretroviral therapy of primary HIV infection (letter)', AIDS, 14, pp. 2406 - 2407
, 2000, 'Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease', Journal of Infectious Diseases, 182, pp. 428 - 434
, 1999, 'Latent reservoirs of HIV infection: Flushing with IL-2?', Nature Medicine, pp. 611 - 612
, 1998, 'Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens', Clinical and Experimental Immunology, 113, pp. 85 - 91
, 1998, 'Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, milticenter study', Journal of Infectious Diseases, 178, pp. 992 - 999, http://jid.oxfordjournals.org/content/178/4/992.full.pdf+html
, 1998, 'Therapeutic strategies for HIV infection - time to think hard. (Editorial)', New England Journal of Medicine, pp. 1319 - 1321
, 1997, 'Drug companies have a duty to continue treatment', British Medical Journal: Clinical Research, pp. 889 - 889
, 1997, 'Immune reconstitution in HIV infection', Current Opinion in Immunology, pp. 568 - 572
, 1997, 'Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection', AIDS Research and Human Retroviruses, 13, pp. 29 - 32
, 1996, 'If it's the virus why aren't we measuring it? [3]', Medical Journal of Australia, 165, pp. 119, http://dx.doi.org/10.5694/j.1326-5377.1996.tb124875.x
, 1996, 'Immune-based therapies in HIV infection: recent developments.', AIDS (London, England), 10 Suppl A, http://dx.doi.org/10.1097/00002030-199601001-00022
, 1996, 'CD8+ lymphocyte responses to antiretroviral therapy of HIV infection', Journal of acquired immune deficiency syndrome and human retrovirology, 13, pp. 320 - 326
, 1996, 'Immune-based therapies in HIV infection', AIDS, 10, pp. S159 - 164, http://dx.doi.org/10.1097/00002030-199601001-00022
, 1996, 'Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy', Journal of Infectious Diseases, 173, pp. 1354 - 1366
, 1995, 'Antiretro viral therapy of human immunodeficiency virus type‐1 (HIV‐1) infection', Australian and New Zealand Journal of Medicine, 25, pp. 344 - 349, http://dx.doi.org/10.1111/j.1445-5994.1995.tb01900.x
, 1995, 'If it's the virus, why aren't we measuring it?', The Medical journal of Australia, 163, pp. 508 - 509, http://dx.doi.org/10.5694/j.1326-5377.1995.tb124712.x
, 1993, 'Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter', New England Journal of Medicine, 329, pp. 297 - 303, http://dx.doi.org/10.1056/NEJM199307293290501
, 1990, 'Studies on the hyperplasia ('regeneration') of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects', Biochemical Journal, 265, pp. 51 - 59, http://dx.doi.org/10.1042/bj2650051
, 1988, 'Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour', Biochemical Journal, 250, pp. 247 - 252, http://dx.doi.org/10.1042/bj2500247
, 1987, 'Effects of αtocopherol on carbon tetrachloride metabolism in rat liver microsomes', Free Radical Research, 3, pp. 325 - 330, http://dx.doi.org/10.3109/10715768709069800
, 1985, 'The effect of cimetidine and ranitidine on paracetamol glucuronidation and sulphation in cultured rat hepatocytes', Biochemical Pharmacology, 34, pp. 1415 - 1421, http://dx.doi.org/10.1016/0006-2952(85)90678-1
Conference Papers
, 2018, 'Pulmonary Effects of Immediate Versus Deferred Antriretroviral Treatment Initiation: Final Follow-Up Results from the Randomized Strategic Timing of Antiretroviral Treatment (START) Pulmonary Substudy', in AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMER THORACIC SOC, CA, San Diego, presented at
, 2016, 'Technical rehearsal of tritium operation at JET', in FUSION ENGINEERING AND DESIGN, ELSEVIER SCIENCE SA, CZECH REPUBLIC, Prague, pp. 196 - 200, presented at
, 2016, '"HIV-1 controllers" - what's their secret?', in EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-BLACKWELL, AUSTRALIA, Melbourne, pp. 74 - 74, presented at
, 2016, 'Fc gamma R ectodomain probes measure anti-viral IgG effector function', in EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-BLACKWELL, AUSTRALIA, Melbourne, pp. 1256 - 1257, presented at
, 2016, 'Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000395394300243&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'PRE-THERAPY INFLAMMATION/COAGULATION ACTIVATION AND LONG-TERM CD4 RESPONSE TO ANTIRETROVIRAL THERAPY', in SEXUALLY TRANSMITTED INFECTIONS, BMJ PUBLISHING GROUP, pp. A73 - A73, http://dx.doi.org/10.1136/sextrans-2015-052270.195
, 2013, 'How occupational therapy can enhance an improving access to psychological therapy service', in BRITISH JOURNAL OF OCCUPATIONAL THERAPY, SAGE PUBLICATIONS LTD, pp. 84 - 84, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000328855900194&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2013, 'Accurate prediction of response to HIV therapy without a genotype: a potential tool for therapy optimization in resource-limited settings', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CANADA, Toronto, pp. A20 - A20, presented at
, 2013, 'Proviral DNA testing of HIV tropism in the Maraviroc Switch Collaborative Study (MARCH) - results of a three-phase quality assurance (QA) programme', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CANADA, Toronto, pp. A144 - A144, presented at
, 2011, 'LOWER FAT MASS AND LOWER BONE FORMATION PREDICT GREATER BONE LOSS WITH TENOFOVIR IN HIV-INFECTED ADULTS', in OSTEOPOROSIS INTERNATIONAL, SPRINGER LONDON LTD, AUSTRALIA, Gold Coast, pp. S614 - S615, presented at
, 2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A7 - A7, presented at
, 2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A7 - A7, presented at
, 2010, 'The development of computational models that accurately predict virological response to HIV therapy to power an online treatment selection tool', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CROATIA, Dubrovnik, pp. A89 - A89, presented at
, 2010, 'The development of computational models that accurately predict virological response to HIV therapy to power an online treatment selection tool', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Dubrovnik, CROATIA, pp. A89 - A89, presented at
, 2009, 'Anthropometric and metabolic outcomes in a 48-week randomized, open-label study of three different combination antiretroviral regimens as initial therapy for HIV infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, PA, Philadelphia, pp. A8 - A9, presented at
, 2009, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir in randomized trials: systematic review and meta-analysis', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, PA, Philadelphia, pp. A58 - A58, presented at
, 2009, 'Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, FL, Ft Myers, pp. A38 - A38, presented at
, 2008, 'Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial', in The Lancet, pp. 1881 - 1893, http://dx.doi.org/10.1016/S0140-6736(08)61591-3
, 2006, 'Metabolic syndrome in HIV-infected patients using IDF and ATPIII criteria: prevalence, discordance and clinical utility', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CA, San Francisco, pp. L4 - L4, presented at
, 2006, 'Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CA, San Francisco, pp. L4 - L4, presented at
, 2005, 'Clinically relevant breakpoints for virco (R) TYPE HIV-1 phenotypic resistance information', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CANADA, Quebec City, pp. S39 - S39, presented at
, 2004, 'Estimation of phenotypic clinical cutoffs for VirtualPhenotype (TM) through meta analyses of clinical trial and cohort data', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, SPAIN, Tenerife, pp. U108 - U109, presented at
Filter by type
https://orcid.org/0000-0001-6072-8309